Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

No Long-Term Benefit to Sentinel Lymph Node Biopsy in Most DCIS Patients

Key clinical point: Sentinel lymph node biopsy (SLNB) is not warranted in women with older patients with ductal carcinoma in situ (DCIS) amenable to breast conservation.

Major finding: With a median follow-up of 5.8 years, there were no significant differences in rates of recurrence, ipsilateral breast cancer, or breast cancer-specific mortality for SLNB versus no SLNB.

Study details: Retrospective study including 12,776 women aged 67-94 years who received a diagnosis of DCIS between 2001 and 2013 and underwent breast-conserving surgery.

Disclosures: The research was funded by an award from the Patient-Centered Outcomes Research Institute (PCORI). Dr. Wang reported no disclosures, while co-authors provided disclosures related to Genentech, Eisai, Pfizer, Jonhson & Johnson, and 21st Century Oncology.

Citation:

Hung P et al. JNCI Cancer Spectr. 2019 Aug 7;3(4):pkz052. doi. 10.1093/jncics/pkz052. https://academic.oup.com/jncics/article/3/4/pkz052/5544720